HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.